open access

Vol 47, No 2 (2016)
Prace poglądowe / Reviews
Submitted: 2016-03-25
Published online: 2016-04-01
Get Citation

Recent developments in diagnostics and monitoring of tyrosine kinase inhibitors treatment response of chronic myeloid leukemia

Joanna Wącław1, Tomasz Sacha
DOI: 10.1016/j.achaem.2016.04.007
·
Acta Haematol Pol 2016;47(2):121-127.
Affiliations
  1. Klinika Hematologii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie, Polska

open access

Vol 47, No 2 (2016)
Prace poglądowe / Reviews
Submitted: 2016-03-25
Published online: 2016-04-01

Abstract

Techniques of molecular biology are of key importance in diagnostics and monitoring of tyrosine kinase inhibitors (TKIs) treatment response of chronic myeloid leukemia (CML). Although much has already been achieved in this field, new prognostic factors and developments in laboratory methods are constantly emerging.

Halving time is a new prognostic factor defined as the rate of BCR-ABL1 decline from baseline, assessed by estimating the number of days over which BCR-ABL1 halved. Among patients with >10% BCR-ABL1 at 3 months of therapy with TKI, the poorest-risk group can be distinguished by the slow rate of BCR-ABL1 decline from baseline. More common use of techniques, such as the whole exome sequencing and transcriptome sequencing will enable assessment of patients’ genetic variation at diagnosis and may contribute to a prognostic score that will allow for optimization of therapy. Digital PCR built on traditional PCR provides highly sensitive absolute quantification of BCR-ABL1 transcript level without the need for standard curves and could further improve the treatment results in patients with CML.

Abstract

Techniques of molecular biology are of key importance in diagnostics and monitoring of tyrosine kinase inhibitors (TKIs) treatment response of chronic myeloid leukemia (CML). Although much has already been achieved in this field, new prognostic factors and developments in laboratory methods are constantly emerging.

Halving time is a new prognostic factor defined as the rate of BCR-ABL1 decline from baseline, assessed by estimating the number of days over which BCR-ABL1 halved. Among patients with >10% BCR-ABL1 at 3 months of therapy with TKI, the poorest-risk group can be distinguished by the slow rate of BCR-ABL1 decline from baseline. More common use of techniques, such as the whole exome sequencing and transcriptome sequencing will enable assessment of patients’ genetic variation at diagnosis and may contribute to a prognostic score that will allow for optimization of therapy. Digital PCR built on traditional PCR provides highly sensitive absolute quantification of BCR-ABL1 transcript level without the need for standard curves and could further improve the treatment results in patients with CML.

Get Citation

Keywords

CML; TKI; Halving time; Treatment response monitoring; Digital PCR

About this article
Title

Recent developments in diagnostics and monitoring of tyrosine kinase inhibitors treatment response of chronic myeloid leukemia

Journal

Acta Haematologica Polonica

Issue

Vol 47, No 2 (2016)

Pages

121-127

Published online

2016-04-01

Page views

156

Article views/downloads

312

DOI

10.1016/j.achaem.2016.04.007

Bibliographic record

Acta Haematol Pol 2016;47(2):121-127.

Keywords

CML
TKI
Halving time
Treatment response monitoring
Digital PCR

Authors

Joanna Wącław
Tomasz Sacha

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl